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ing doesn’t tell us why some country like UK perform well while others like France 
don’t. ConClusions: Our results underline the country difference of arbitration 
between public policies such as public health, and industrial or innovation policy. 
Among tested variables, it appears that the regulation of drug pricing and market 
access, or the macroeconomic impact of pharmaceutical industry in a country con-
tribute to determine the scope of HTA policies.
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Excessive smoking and alcohol consumption were the traditional causal factors in 
many head and neck cancers in the United States and Western Europe. However, 
the Human papilloma Virsus (HPV) is now responsible for up to 80% of cancers of 
the oropharynx. HPV-related oropharyngeal cancers are a distinct clinical, epide-
miological and molecular entity. This poster will show that the metrics used to 
describe the burden of a cancer to policy makers are very nuanced. As the patients 
with HPV-associated oropharyngeal cancers are younger and healthier individuals, 
they have been shown to have a better prognosis than traditional head and neck 
cancers. The goal of treatment has shifted from mortality to morbidity in these can-
cers. Measures of morbidity (functional status) are now important considerations in 
treatment options. This poster will compare and contrast various epidemiological 
measures - Incidence /100,000, Prevalence, Years of Life Lost, Mortality to Incidence 
Ratio with respect to HPV-related and unrelated head and neck cancers. Finally, 
we will discuss the economic metrics (e.g. Disability adjusted life years, Years of 
working age lost) used to portray a cancer and make a link with research funding 
in various countries. The question posed is whether mortality or morbidity should 
predominate in resource/research allocation decisions?
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objeCtives: How health care decision makers arrange their appraisal process of 
new health care technologies have direct impact on population health. However, 
no consensus exists on how the appraisal process should be designed to maxim-
ise population health or societal welfare. The purpose of this work is to develop 
a simple analytic framework that enables analysis of the different stakeholders’ 
(decision makers and manufacturers) payoffs from alternative appraisal pro-
cesses. Methods: The analytic framework outlined in the paper is based on 
viewing the appraisal processes as a diagnostic test aimed at identifying cost-
effective (true positives) and cost-ineffective (true negative) technologies. Based 
on this characterisation pay-off functions are formalised to analyse how design 
and operation of the appraisal process impacts population health and manufac-
turers’ earnings. Results: The framework identifies those factors that have the 
greatest influence on population health and manufactures payoffs and illustrates 
how this leads to conflicting interests towards how the appraisal process should 
be set up and operated. It is demonstrated that there is no uniquely optimal way 
to design and operate the appraisal of new health care technologies, since optimal 
design and operation depends on the price of technologies that undergo appraisal. 
The analysis also shows that operating a given reimbursement system implies a 
trade-off between incentivising cost-effective pricing (pricing below the threshold/
willingness to pay) and rejecting more cost-effective technologies (increasing the 
proportion of false negatives). It is further demonstrated how the framework can 
be used to gain insight into current policy questions including who should bear the 
burden of proof and how rigorous the process should be. ConClusions: There is 
no unique way to design and operate the appraisal of health care technologies in 
order to maximise population health or societal welfare. Improving health or soci-
etal welfare through the appraisal process requires careful consideration of payoffs 
and incentives of all stakeholders.
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objeCtives: The generation of evidence in the early development of a technology 
is a bottle neck for uncertainty in decision making. Health economic modeling can 
support the assessment of early innovation, but complex modeling approaches are 
criticized for being “black boxes” which in turn reduce their acceptance in health 
policy. Methods: MCDA can address the gap about what matters to health care 
decision makers and data collection by explicitly structuring decision criteria. The 
combination of MCDA modeling and health economic modeling implies a potential 
for gaining efficiency. The simulation model of the intervention for stroke, the MSU, 
is analyzed regarding application of MCDA. Results: Experts and stakeholders can 
support the: 1) Definition of model factors e.g. outcome parameter, which is gener-
ally accepted (Barthel-Index for Stroke outcome); 2) Evidence collection e.g. is the 
data valid? (outcome of thrombolysis); 3) Model structure e.g. interrelation between 
input parameters (stroke incidence, risk factors and population); 4) Validation of 
a model e.g. reassessment of step 1-3; and 5) Final analysis by using MCDA e.g. 
importance of economic vs. medical benefit. ConClusions: The methodological 
combination is advantageous because simulation modeling as well as MCDA have 
a similar sequence of events. The simulation output, which is commonly validated 
by technical and medical experts, can gain validity by the heterogeneous perspec-
tives of participating stakeholders in the validation process. For example, this raises 
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bACkgRound: Colorectal cancer (CRC) screening in Spain uses a fecal-occult 
blood test (FOBT) for screening and colonoscopy as diagnostic tool. Adenomas 
constitute the most frequent findings of this colonoscopy, and the removal of 
these premalignant lesions is considered the main contributor to the reduction 
of mortality and incidence of CRC. There is no clear agreement regarding the 
risk classification of adenomas as well as the optimal surveillance strategy for 
each degree of risk. Genomics may contribute to further delineate individual risk, 
and its characterization is crucial for improving the effectiveness of surveillance 
strategies by targeting individuals who would benefit the most. objeCtive: To 
optimize, within a CRC screening program, surveillance of premalignant lesions 
using individual risk-based strategies, based on genetic analysis, that take into 
account benefits, harms and costs. Methods: A discrete-event simulation model 
that reproduces the process of screening and takes into account the costs at every 
stage, from invitation to screening to surveillance of findings will be upgraded. 
The natural history of the disease will be included, with special emphasis on the 
events after adenoma detection at screening colonoscopy. Based on the results of a 
study aimed at identifying common genetic variants associated with an increased 
susceptibility to develop colorectal adenomas, the risk of developing cancer or 
recurrent adenomas according to the clinical characteristics of the patients will 
be included in the model. The interval between surveillance colonoscopies will 
be optimized with the objective of minimizing the number of colonoscopies while 
keeping the same level of effectiveness, defined as the impact on incidence of 
advanced adenomas and cancer over time. IMPLICATIONS: Simulation models 
can help in the design of personalized screening strategies. Personalizing CRC 
screening through surveillance strategies may improve allocation of resources 
under cost constraints, minimize harms and maximize benefits of population-
based programs, affecting millions of people.
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For nearly 25 years, the most effective tool for containing public spending on 
pharmaceutical drugs in Germany is the formation of fixed reference price groups 
(FRPG) - the annual savings have continuously risen from 0.31 billion Euros in 1990 
to 4.32 billion Euros in 2009. Hereunder, the so-called “jumbo groups” (patent-free 
and patented substances) that were introduced with the SHI Modernization Act 
of 2004 have been of high importance. With the recently published, first-time call 
for benefit assessments of substances in the established market (April 2013), the 
Federal Joint Committee (FJC) has yet launched another potent mean of reducing 
costs. Unlike the early benefit assessment of new active ingredients where several 
substances have undergone scrutiny since January 2011, it is unclear what the 
outlook is for the substances in the established market. Therefore, the objective of 
the presentation is to assess whether a FRPG or a benefit assessment is to be pre-
ferred by pharmaceutical companies for established substances. Fixed reference 
price scenarios are calculated for therapeutically comparable substance classes 
within the call for benefit assessment of substances in the established German 
drug market. For the established substances, a risk assessment and benchmark 
is performed based on the criteria in the code of procedure of the FJC and the 
assessment of new active ingredients, respectively. The results of the ongoing FRPG 
scenario evaluation will be displayed as bar charts by savings in € . The risk assess-
ment is displayed in a tabular format. Apart from discussing the results of the 
FRPG calculations compared to the benefit assessment of established substances, 
the presentation discusses implications for international reference pricing, since 
the German market has been regarded as the last bastion of free pharmaceutical 
pricing for a long time.
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objeCtives: Socioeconomic factors are important components of Health 
Technology Assessment’s (HTA) institutionalization. If most of the countries 
have established HTA agencies, they required scientific expertise to emerge and 
become institutionalized. In a previous scientometric work, we did an analysis 
of scientific conditions of HTA emergence in the scientific literature. Our obser-
vation allowed us to link HTA research capacity and HTA institutionalization in 
a given country. Methods: In order to explore endogenous as well exogenous 
factors sustaining HTA expertise, we undertake a principal component analysis 
as multivariate analysis technique in order to establish which variable are more 
appropriate for the assessment of scientific expertise in the context of HTA public 
policy. Results: HTA national public policy could be ranked according to their 
academic expertise. Country HTA publications productivity matched in comparison 
with health expenses & gross product in several countries. Nevertheless this rank-
